Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16330256 | 0.89 | LMNA (0.48) | LMNAPOLBSMN1; SMN2CYP1A2HPGD | |
| SCHEMBL13117641 | 0.76 | CTSK (0.56) | LMNAMAPTRAB9A | |
| SCHEMBL12401676 | 0.73 | CTSK (0.41) | LMNAMAPTRAB9A | |
| SCHEMBL12401711 | 0.73 | ALDH1A1 (0.47) | POLBSMN1; SMN2CYP1A2HPGDALDH1A1 | |
| SCHEMBL6407970 | 0.72 | POLB (0.59) | LMNAPOLBSMN1; SMN2CYP1A2HPGD | |
| SCHEMBL12401725 | 0.70 | RAB9A (0.57) | LMNASMN1; SMN2ALDH1A1HTTL3MBTL1 | |
| SCHEMBL12401673 | 0.70 | CTSK (0.59) | LMNAPOLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6409325 | 0.69 | NPC1 (0.64) | LMNAPOLBSMN1; SMN2CYP1A2HPGD | |
| SCHEMBL6403149 | 0.69 | NPC1 (0.57) | LMNAPOLBSMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL6410101 | 0.69 | POLB (0.54) | LMNAPOLBSMN1; SMN2CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | LMNA 2814/4885POLB 3945/4885SMN1; SMN2 2265/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | LMNA 2850/4885POLB 4161/4885SMN1; SMN2 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.